Sharekhan's research report on Aurobindo Pharma
Strong growth momentum across the US and Europe business are likely to sustain going ahead driven by tractions expected in injectables space, new facilities, a strong product pipeline and gradual pick up in complex generics. Further, the expected commissioning of the vaccine manufacturing facility by end of July 2021 would open a new growth avenue and would add to the topline. Improving growth prospects, better earnings visibility and a strengthening balance sheet are the key positives for the company.
Outlook
We retain our Buy recommendation on the stock of Aurobindo Pharma with a revised PT of Rs. 1,185.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
